2025
SJR Q1
JCR Q1 · 5,8
12 matched articles
SCIE
Journal detail
Molecular Cancer Research
- Publisher
- American Association for Cancer Research Inc.
- Country
- United States · Northern America
- Type
- journal
- ISSN
-
1541778615573125
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 1,759
- Quartile Q1
- H-Index 162
- Cites/doc 5,65
- Docs (3y) 338
- Cites (3y) 1.740
Clarivate
Web of Science · JCR · 2025
- JCR Q Q1
- JIF 5,8
- 5Y JIF 5,2
- JCI 0,83
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Cancer Research Q1
- Molecular Biology Q1
- Oncology Q1
Areas
- Biochemistry, Genetics and Molecular Biology
- Medicine
WoS categories
- Oncology | Cell Biology
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q1 | 1,759 | 5,8 | 5,2 | 0,83 | Q2 | 162 |
| 2024 | Q1 | Q1 | 1,748 | 4,7 | 4,9 | 0,83 | Q2 | 156 |
| 2023 | Q1 | Q2 | 1,66 | 4,1 | 4,8 | 0,89 | Q2 | 156 |
| 2022 | Q1 | Q2 | 1,668 | 5,2 | 5,7 | 0,94 | Q2 | 156 |
| 2021 | Q1 | Q2 | 1,805 | 6,3 | 6,8 | 1,04 | Q1 | 156 |
| 2020 | Q1 | Q2 | 2,273 | 5,9 | 6,1 | 1,05 | Q2 | 156 |
| 2019 | Q1 | Q2 | 2,389 | 4,6 | 4,8 | 1,03 | Q2 | 156 |
| 2018 | — | Q2 | — | 4,5 | 4,6 | 1,05 | Q2 | — |
| 2017 | Q1 | Q2 | 2,428 | 4,6 | 4,6 | 1,03 | Q2 | 156 |
| 2016 | Q1 | Q1 | 2,496 | 5 | 5 | — | — | 156 |
| 2015 | Q1 | Q1 | 2,588 | 4,5 | 4,9 | — | — | 156 |
| 2014 | Q1 | Q1 | 2,728 | 4,4 | 4,9 | — | — | 156 |
| 2013 | Q1 | Q1 | 2,803 | 4,5 | 4,8 | — | — | 156 |
| 2012 | Q1 | Q1 | 2,751 | 4,4 | 4,9 | — | — | 156 |
| 2011 | Q1 | Q1 | 2,753 | 4,3 | 4,5 | — | — | 156 |
| 2010 | Q1 | Q1 | 3,096 | 4,4 | 4,7 | — | — | 156 |
| 2009 | — | Q1 | — | 4,2 | 4,5 | — | — | — |
| 2008 | — | Q1 | — | 4,5 | 5,2 | — | — | — |
| 2007 | — | Q2 | — | 4,3 | 5,3 | — | — | — |
| 2006 | — | Q1 | — | 4,8 | — | — | — | — |
| 2005 | — | Q1 | — | 5,4 | — | — | — | — |
| 2004 | — | Q1 | — | 4,8 | — | — | — | — |
| 2003 | — | Q3 | — | 2,1 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | CELL BIOLOGY | SCIE | Q2 | Q2 | 64/207 |
| 2025 | ONCOLOGY | SCIE | Q1 | Q2 | 67/333 |
| 2024 | CELL BIOLOGY | SCIE | Q2 | Q2 | 72/204 |
| 2024 | ONCOLOGY | SCIE | Q1 | Q2 | 77/328 |
| 2023 | CELL BIOLOGY | SCIE | Q2 | Q2 | 84/205 |
| 2023 | ONCOLOGY | SCIE | Q2 | Q2 | 92/322 |
| 2022 | CELL BIOLOGY | SCIE | Q2 | Q2 | 73/191 |
| 2022 | ONCOLOGY | SCIE | Q2 | Q2 | 72/241 |
| 2021 | CELL BIOLOGY | SCIE | Q2 | Q2 | 65/195 |
| 2021 | ONCOLOGY | SCIE | Q2 | Q1 | 64/245 |
| 2020 | CELL BIOLOGY | SCIE | Q2 | Q2 | 61/195 |
| 2020 | ONCOLOGY | SCIE | Q2 | Q2 | 68/242 |
| 2019 | CELL BIOLOGY | SCIE | Q2 | Q2 | 64/195 |
| 2019 | ONCOLOGY | SCIE | Q2 | Q2 | 75/244 |
| 2018 | CELL BIOLOGY | SCIE | Q2 | Q2 | 66/193 |
| 2018 | ONCOLOGY | SCIE | Q2 | Q2 | 65/230 |
| 2017 | CELL BIOLOGY | SCIE | Q2 | Q2 | 59/190 |
| 2017 | ONCOLOGY | SCIE | Q2 | Q2 | 57/223 |
| 2016 | CELL BIOLOGY | SCIE | Q2 | — | 50/190 |
| 2016 | ONCOLOGY | SCIE | Q1 | — | 49/217 |
| 2015 | CELL BIOLOGY | SCIE | Q2 | — | 51/187 |
| 2015 | ONCOLOGY | SCIE | Q1 | — | 44/213 |
| 2014 | CELL BIOLOGY | SCIE | Q2 | — | 63/184 |
| 2014 | ONCOLOGY | SCIE | Q1 | — | 44/211 |
| 2013 | CELL BIOLOGY | SCIE | Q2 | — | 61/185 |
| 2013 | ONCOLOGY | SCIE | Q1 | — | 45/203 |
| 2012 | CELL BIOLOGY | SCIE | Q2 | — | 59/185 |
| 2012 | ONCOLOGY | SCIE | Q1 | — | 46/197 |
| 2011 | CELL BIOLOGY | SCIE | Q2 | — | 62/181 |
| 2011 | ONCOLOGY | SCIE | Q1 | — | 42/196 |
| 2010 | CELL BIOLOGY | SCIE | Q2 | — | 64/178 |
| 2010 | ONCOLOGY | SCIE | Q1 | — | 42/185 |
| 2009 | CELL BIOLOGY | SCIE | Q2 | — | 57/162 |
| 2009 | ONCOLOGY | SCIE | Q1 | — | 41/166 |
| 2008 | CELL BIOLOGY | SCIE | Q2 | — | 46/157 |
| 2008 | ONCOLOGY | SCIE | Q1 | — | 35/143 |
| 2007 | CELL BIOLOGY | SCIE | Q2 | — | 43/156 |
| 2007 | ONCOLOGY | SCIE | Q2 | — | 36/132 |
| 2006 | CELL BIOLOGY | SCIE | Q2 | — | 40/156 |
| 2006 | ONCOLOGY | SCIE | Q1 | — | 26/127 |
| 2005 | CELL BIOLOGY | SCIE | Q1 | — | 31/153 |
| 2005 | ONCOLOGY | SCIE | Q1 | — | 16/123 |
| 2004 | CELL BIOLOGY | SCIE | Q1 | — | 36/155 |
| 2004 | ONCOLOGY | SCIE | Q1 | — | 18/123 |
| 2003 | CELL BIOLOGY | SCIE | Q3 | — | 87/156 |
| 2003 | ONCOLOGY | SCIE | Q3 | — | 62/120 |